Cusabio COVID-19

Research Solutions for Coronavirus – Cusabio

Cusabio COVID-19 RUO Detection Kits (IgG/IgM and qPCR based)

Supplier Code Name Test type Size Price
Cusabio SF010025 SARS-CoV-2 Nucleic Acid Dual-Detection Kit(Real-Time PCR Method) RT-PCR based test kit 25T/kit £261
Cusabio SF010050 SARS-CoV-2 Nucleic Acid Dual-Detection Kit(Real-Time PCR Method) RT-PCR based test kit 50T/kit £522

On 26 November 2021, WHO designated the variant B.1.1.529 -the newest COVID-19 “variant of concern” , named Omicron.

Why are scientists worried about it?

Omicron (B.1.1.529) was first detected in Southern Africa. Omicron’s rapid rise in South Africa is what worries researchers most. Cases have also been reported in Botswana, but also in Israel, Belgium, the U.K., even Hong Kong. So far, the virus has been detected in more than 30 countries and at least 9 states. The COVID-19 Omicron variant has already made its way across the globe.

What scientists know so far?

The B.1.1.529 variant carries more than 30 mutations in the Spike protein, which is has an unprecedented number of mutations compared to Delta. It’s critically important to understand whether these mutations allow the Omicron variant to escape from neutralizing antibodies. It is not yet clear about the Transmissibility and Severity of disease.
Does Omicron boast faster transmission and stronger resistance to established immunity? Omicron is a big unknown.

Omicron (B.1.1.529) Reagents: CUSABIO are Starting to Take Pre-Orders!

At present, epidemiologists, Laboratorians and researchers worldwide are conducting studies to better understand many aspects of Omicron. To support the study of Omicron variants, CUSABIO is developing Omicron Variants related products. We’re starting to take Pre-orders now. Pre-orders will allow you to guarantee immediate shipment on release. Here is the collection for the most popular SARS-CoV-2 Omicron products. Please Contact Us for Pre-Orders.

Code Product Name Target Antigen Source Region and Mutations
CSB-YP3325GMY(M18) Recombinant Human Novel Coronavirus Nucleoprotein(N) Omicron Variant Nucleoprotein Yeast 1-419aa(P13L, Δ31-33, R203K, G204R)
CSB-EP3325GMY(M18) Recombinant Human Novel Coronavirus Nucleoprotein(N) Omicron Variant Nucleoprotein E-Coli 1-419aa(P13L, Δ31-33, R203K, G204R)
CSB-BP3325GMY(M18) Recombinant Human Novel Coronavirus Nucleoprotein(N) Omicron Variant Nucleoprotein Baculovirus 1-419aa(P13L, Δ31-33, R203K, G204R)
CSB-MP3325GMY(M18) Recombinant Human Novel Coronavirus Nucleoprotein(N) Omicron Variant Nucleoprotein Mammalian 1-419aa(P13L, Δ31-33, R203K, G204R)
CSB-YP3324GMY9(M) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron Variant Spike glycoprotein Yeast 13-303aa(A67V, Δ69-70, T95I, G142D, Δ143-145, ΔN211, L212I, ins214EPE)
CSB-EP3324GMY9(M) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron Variant Spike glycoprotein E-Coli 13-303aa(A67V, Δ69-70, T95I, G142D, Δ143-145, ΔN211, L212I, ins214EPE)
CSB-BP3324GMY9(M) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron Variant Spike glycoprotein Baculovirus 13-303aa(A67V, Δ69-70, T95I, G142D, Δ143-145, ΔN211, L212I, ins214EPE)
CSB-MP3324GMY9(M) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron Variant Spike glycoprotein Mammalian 13-303aa(A67V, Δ69-70, T95I, G142D, Δ143-145, ΔN211, L212I, ins214EPE)
CSB-YP3324GMY1(M14) Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein Yeast 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-EP3324GMY1(M14) Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein E-Coli 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-BP3324GMY1(M14) Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein Baculovirus 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-MP3324GMY1(M14) Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein Mammalian 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-EP3324GMY1(M14)-B Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein E-Coli 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-MP3324GMY1(M14)-B Recombinant Human Novel Coronavirus Spike glycoprotein(S)(B.1.1.529) Partial Spike glycoprotein Mammalian 319-541aa(G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
CSB-YP3324GMY(M7) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron, Partial Spike glycoprotein Yeast 16-685aa(A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214-215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H);
CSB-EP3324GMY(M7) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron, Partial Spike glycoprotein E-Coli 16-685aa(A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214-215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H);
CSB-BP3324GMY(M7) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron, Partial Spike glycoprotein Baculovirus 16-685aa(A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214-215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H);
CSB-MP3324GMY(M7) Recombinant Human Novel Coronavirus Spike glycoprotein(S) Omicron, Partial Spike glycoprotein Mammalian 16-685aa(A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214-215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H);
Product Name Code Sample Types Assay Principle
SARS-CoV-2 N IgG Antibody ELISA Kit CSB-EL3325HU serum, plasma Qualitative
SARS-CoV-2 N ELISA Kit CSB-EL33251 serum, plasma, swabs Quantitative
Human SARS-CoV-2 S RBD Ab (IgG) ELISA Kit CSB-EL33241HU serum, plasma Qualitative
Human SARS-CoV-2 S RBD Ab (IgM) ELISA Kit CSB-EL33242HU serum, plasma Qualitative
Human SARS-CoV-2 Neutralizing Antibody ELISA Kit CSB-EL33243HU serum, plasma Qualitative
Human SARS-CoV-2 N/S1 Ab (IgG) ELISA Kit CSB-EL3326HU serum, plasma Qualitative
SARS-CoV-2 S1 RBD ELISA Kit CSB-EL33244 serum, plasma, swabs Quantitative
Target Name Product Name Code Species Source Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein(N) CSB-EP3325GMY SARS-CoV-2 E.coli N-terminal His-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein(N) CSB-YP3325GMY SARS-CoV-2 Yeast N-terminal His-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein(N) CSB-BP3325GMY SARS-CoV-2 Baculovirus N-terminal His-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein(N) CSB-MP3325GMY SARS-CoV-2 Mammalian cell N-terminal His-tagged
S Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-YP3324GMY SARS-CoV-2 Yeast N-terminal His-tagged
S Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-BP3324GMY SARS-CoV-2 Baculovirus N-terminal His-tagged
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-MP3324GMY1 SARS-CoV-2 Mammalian cell C-terminal 6xHis-mFc-tagged
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-MP3324GMY1b1 SARS-CoV-2 Mammalian cell N-terminal 10xHis-tagged and C-terminal Myc-tagged
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-YP3324GMY1 SARS-CoV-2 Yeast N-terminal 6xHis-sumostar-tagged
S (S1) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-YP3324GMYa4 SARS-CoV-2 Yeast N-terminal 6xHis-sumostar-tagged
S (S1) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-MP3324GMY SARS-CoV-2 Mammalian cell N-terminal 10xHis-tagged and C-terminal Flag-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein(N),partial CSB-EP3325GMY1 SARS-CoV-2 E.coli
N Recombinant Human Novel Coronavirus Nucleoprotein(N),Biotinylated CSB-EP3325GMY-B SARS-CoV-2 E.coli
NSP3 Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 3(nsp3),partial CSB-EP3398GND SARS-CoV-2 E.coli
NSP5 Recombinant Severe acute respiratory syndrome coronavirus 2 3C-like proteinase(NSP5) CSB-EP3389GND SARS-CoV-2 E.coli
Nsp9 Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 9(nsp9) CSB-MP3388GND SARS-CoV-2 Mammalian cell
Nsp9 Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 9(nsp9) CSB-EP3388GND SARS-CoV-2 E.coli
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V367F), partial CSB-MP3324GMY1(M1) SARS-CoV-2 Mammalian cell
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (W436R), partial CSB-MP3324GMY1(M2) SARS-CoV-2 Mammalian cell
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (G476S), partial CSB-MP3324GMY1(M4) SARS-CoV-2 Mammalian cell
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (N501Y), partial CSB-MP3324GMY1(M6) SARS-CoV-2 Mammalian cell
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V483A), partial CSB-MP3324GMY1(M5) SARS-CoV-2 Mammalian cell
S (RBD) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial,Biotinylated CSB-MP3324GMY1-B SARS-CoV-2 Mammalian cell
S (S1) Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial CSB-YP3324GMYa4 SARS-CoV-2 Yeast
S (S1) Recombinant Human Novel Coronavirus Spike glycoprotein(S) (D614G), partial CSB-MP3324GMY(M1) SARS-CoV-2 Mammalian cell
S (S1) Recombinant Human Novel Coronavirus Spike glycoprotein(S)(N501Y,P681H), partial CSB-MP3324GMY(M2) SARS-CoV-2 Mammalian cell
Product Name Code Reactivity Species Tested Applications
N Antibody CSB-RA33255A0GMY SARS-CoV-2 ELISA
N Antibody CSB-RA33255A1GMY SARS-CoV-2 ELISA, WB, GICA
N Antibody, Biotin conjugated CSB-RA33255D1GMY SARS-CoV-2 ELISA
N Antibody, FITC conjugated CSB-RA33255C1GMY SARS-CoV-2 ELISA
N Antibody, HRP conjugated CSB-RA33255B1GMY SARS-CoV-2 ELISA
S Antibody CSB-RA33245A0GMY SARS-CoV-2 ELISA
S Antibody CSB-RA33245A1GMY SARS-CoV-2 ELISA, GICA, Neutralization
Spike RBD Nanobody CSB-RA33245A2GMY SARS-CoV-2 ELISA, GICA, Neutralization
S Antibody, Biotin conjugated CSB-RA33245D1GMY SARS-CoV-2 ELISA
S Antibody, FITC conjugated CSB-RA33245C1GMY SARS-CoV-2 ELISA
S Antibody, HRP conjugated CSB-RA33245B1GMY SARS-CoV-2 ELISA
N Antibody CSB-RA33255A2GMY SARS-CoV-2 ELISA
SARS-CoV-2 RBD Nanobody, Biotin conjugated CSB-RA33245D2GMY SARS-CoV-2 ELISA
SARS-CoV-2 RBD Nanobody, FITC conjugated CSB-RA33245C2GMY SARS-CoV-2 ELISA
SARS-CoV-2 RBD Nanobody, HRP conjugated CSB-RA33245B2GMY SARS-CoV-2 ELISA
SARS-CoV-2 Spike RBD Antibody Pair 1 CSB-EAP33245 SARS-CoV-2 S-ELISA
SARS-CoV-2 N Antibody Pair 1 CSB-EAP33255A1 SARS-CoV-2 S-ELISA
SARS-CoV-2 N Antibody Pair 2 CSB-EAP33255A2 SARS-CoV-2 S-ELISA
SARS-CoV-2 N Antibody Pair 3 CSB-EAP33255A3 SARS-CoV-2 S-ELISA
SARS-CoV-2 N Antibody Pair 4 CSB-EAP33255A4 SARS-CoV-2 S-ELISA

Product Name Code Tested Applications Raised in
S Monoclonal Antibody CSB-MA33245A0m GICA Mouse
S Monoclonal Antibody CSB-MA33245A1m GICA Mouse
S Monoclonal Antibody CSB-MA33245A2m GICA Mouse
S Antibody CSB-PA33245YA01GMY GICA Rabbit
S Antibody CSB-PA33245YA11GMY GICA Rabbit
N Antibody CSB-PA33254A0Rb GICA Rabbit
N Antibody CSB-MA33255A0m GICA Mouse
N Antibody CSB-MA33255A1m GICA Mouse
N Antibody CSB-MA33255A2m GICA Mouse
Partial popular mutants from SARS-CoV-2 Variants

Partial popular mutants from SARS-CoV-2 Variants

The COVID19 epidemic that broke out at the end of 2019 is still raging around the world. The cause of this epidemic, the SARS-CoV-2, has an astonishing speed of mutation. It took just over a year to use nearly 1/2 of the Greek alphabet, and developed from Alpha to Lambda.

At the end of December 2020, the SARS-CoV-2 variant Alpha was discovered in the United Kingdom, and the epidemic in the United Kingdom suddenly got out of control. Then, South Africa discovered Beta, India discovered Delta, and Peru discovered Lambda.

Aiming at the main variants of the SARS-CoV-2 in the world, CUSABIO has developed and produced a series of high-quality mutant antigens with various tag. Most of these mutant antigens have been validated in bioactivity.

SARS-CoV-2 Lambda | C.37 (South America)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) CSB-EP3325GMY(M12) E.coli R203K, G204R N-terminal 6xHis-tagged

SARS-CoV-2 Delta | B.1.617.2 (India)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (D63G,R203M,D377Y) (Active) CSB-EP3325GMY(M14) E.coli D63G, R203M, D377Y N-terminal 6xHis-tagged

SARS-CoV-2 Kappa | B.1.617.1 (India)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203M,D377Y) (Active) CSB-EP3325GMY(M13) E.coli R203M, D377Y N-terminal 6xHis-tagged

SARS-CoV-2 Alpha | B.1.1.7 (U.K)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (D3L,R203K,G204R,S235F) (Active) CSB-EP3325GMY(M1) E.coli D3L, R203K, G204R, S235F N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) CSB-EP3325GMY(M12) E.coli R203K, G204R N-terminal 6xHis-tagged
S1 Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) CSB-MP3324GMY(M1) Mammalian cell D614G C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6) Mammalian cell N501Y C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6)k2 Mammalian cell N501Y C-terminal 6xHis-mFC-tagged

SARS-CoV-2 Beta | B.1.351 (South Africa)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (D3L,R203K,G204R,S235F) (Active) CSB-EP3325GMY(M1) E.coli D3L, R203K, G204R, S235F N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) CSB-EP3325GMY(M12) E.coli R203K, G204R N-terminal 6xHis-tagged
S1 Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) CSB-MP3324GMY(M1) Mammalian cell D614G C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6) Mammalian cell N501Y C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6)k2 Mammalian cell N501Y C-terminal 6xHis-mFC-ta

SARS-CoV-2 Gamma | P.1 (Brazil)

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (P80R) (Active) CSB-EP3325GMY(M3) E.coli P80R N-terminal 6xHis-tagged
S1 Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) CSB-MP3324GMY(M1) Mammalian cell D614G C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6) Mammalian cell N501Y C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) CSB-MP3324GMY1(M6)k2 Mammalian cell N501Y C-terminal 6xHis-mFC-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein(S)(E484K),partial CSB-MP3324GMY1(M8) Mammalian cell E484K C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein(S) (E484K), partial (Active) CSB-MP3324GMY1(M8)h8 Mammalian cell E484K C-terminal mFC-tagged

Other SARS-CoV-2 Variants

 

Target Product Name Code Source Mutation Tag Info
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (P13L) (Active) CSB-EP3325GMY(M4) E.coli P13L N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (D103Y) (Active) CSB-EP3325GMY(M5) E.coli D103Y N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (L230F) (Active) CSB-EP3325GMY(M9) E.coli L230F N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (I292T) (Active) CSB-EP3325GMY(M10) E.coli I292T N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (Q384H) (Active) CSB-EP3325GMY(M11) E.coli Q384H N-terminal 6xHis-tagged
N Recombinant Human Novel Coronavirus Nucleoprotein (N) (S202N) (Active) CSB-EP3325GMY(M8) E.coli S202N N-terminal 6xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (V367F),partial (Active) CSB-MP3324GMY1(M1) Mammalian cell V367F C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (W436R), partial (Active) CSB-MP3324GMY1(M2) Mammalian cell W436R C-terminal 10xHis-tagged
S1-RBD Recombinant Human Novel Coronavirus Spike glycoprotein (S) (G476S), partial (Active) CSB-MP3324GMY1(M4) Mammalian cell G476S C-terminal 10xHis-tagged

Partial Validated Data

● Recombinant SARS-CoV-2 Nucleoprotein (N)(R203K,G204R) (Active) (CSB-EP3325GMY(M12))

Its purity is greater than 96% as determined by SDS-PAGE.

Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 6.775-13.04 ng/ml.

Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 4.664-8.256 ng/ml.

● Recombinant SARS-CoV-2 Nucleoprotein (N)(D63G,R203M,D377Y) (Active) (CSB-EP3325GMY(M14))

Its purity is greater than 85.7% as determined by SDS-PAGE.

Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 3.834 – 5.294 ng/ml.

Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 1.304 – 1.875 ng/ml ng/ml.

● Recombinant SARS-CoV-2 Spike glycoprotein(S) (E484K), partial (Active) (CSB-MP3324GMY1(M8)h8)

Its purity is greater than 90% as determined by SDS-PAGE.

Its binding ability measured by functional ELISA with human ACE2 at 2 μg/ml, the EC50 is 6.597-8.187 ng/ml.

Its binding ability measured by functional ELISA with Biotin-S Antibody at 2 μg/ml, the EC50 is 118.7 ng/ml.

Coronavirus Related Products

Target Name Product Name Code Species Source Tag Info
HE Recombinant Bovine coronavirus Hemagglutinin-esterase(HE) CSB-YP323648BJK BCoV Yeast N-terminal 6xHis-tagged
N Recombinant Bovine coronavirus Nucleoprotein(N) CSB-EP320768BJK BCoV E.coli N-terminal 6xHis-tagged
Orf1ab Recombinant Middle East respiratory syndrome-related coronavirus Orf1ab,partial CSB-EP320768BJK MERS-CoV E.coli Tag-Free
S Recombinant Human coronavirus OC43 Spike glycoprotein(S) ,partial CSB-EP336163HIY HCoV-OC43 E.coli N-terminal 6xHis-SUMO-tagged
S Recombinant Human coronavirus OC43 Spike glycoprotein(S) ,partial CSB-YP336163HIY HCoV-OC43 Yeast N-terminal 6xHis-tagged
S Recombinant Bovine coronavirus Spike glycoprotein(S) ,partial CSB-EP333052BJO BCoV E.coli N-terminal 6xHis-tagged
S Recombinant Bovine coronavirus Spike glycoprotein(S),partial CSB-EP322803BJK BCoV E.coli N-terminal 10xHis-tagged
SARS-COV-RBD Recombinant Human SARS coronavirus Spike glycoprotein(S) ,partial CSB-MP348663HQE SARS-CoV Mammalian cell  
Product Name Code Species Reactivity Tested Applications
S Antibody CSB-PA333052LA01BJO Bovine coronavirus ELISA
S Antibody CSB-PA322803LA01BJK Bovine coronavirus ELISA, WB
S Antibody CSB-PA336163EA01HIY Human coronavirus OC43 ELISA

Coronavirus-Host Interactome Targets Products

Product Name Code Sample Types Detection Range
Human ACE2 ELISA Kit CSB-E04489h serum, plasma, cell culture supernates 0.156 ng/mL-10 ng/mL
Human APN ELISA kit CSB-EL001827HU serum, plasma, tissue homogenates 31.25 pg/mL-2000 pg/mL
Human CD147 ELISA Kit CSB-E12994h serum, plasma 12.5 pg/mL-800 pg/mL
Human CTSB ELISA kit CSB-E13450h serum, plasma, tissue homogenates 0.312 ng/mL-20 ng/mL
Human NRP1 ELISA kit CSB-EL016091HU serum, plasma, tissue homogenates 6.25 pg/mL-400 pg/mL
Product Name Code Species Reactivity Tested Applications
ACE2 Antibody CSB-PA866317LA01HU Human ELISA, IHC, IF
ACE2 Antibody CSB-PA001150GA01HU Human, Mouse, Rat ELISA,WB
APN Antibody CSB-PA001827LA01HU Human, Mouse ELISA, WB, IHC, IF
APN Antibody CSB-PA001827GA01HU Human,Mouse,Rat ELISA,WB
CD147 antibody CSB-PA11759A0Rb Human ELISA, WB, IHC
CTSB Antibody CSB-PA06974A0Rb Human, Mouse ELISA, WB, IHC, IF
DPP4 Antibody CSB-PA06229A0Rb Human, Rat ELISA, WB, IHC, IF
DPP4 Antibody CSB-PA007139GA01HU Human,Mouse,Rat ELISA,WB,IHC
TMPRSS2 Antibody CSB-PA971239 Human ELISA,WB
NRP1 Antibody CSB-PA016091ESR1HU Human ELISA, IHC
Target Name Product Name Code Species Source Tag Info
ACE2 Recombinant Human Angiotensin-converting enzyme 2(ACE2),partial CSB-AP005671HU Human Mammalian cell C-terminal 6xHis-tagged
CD147 Recombinant Human Basigin(BSG),partial CSB-RP117574h Human E.coli N-terminal 6xHis-tagged
CTSB Recombinant Human Cathepsin B(CTSB),partial (Active) CSB-AP005381HU Human Mammalian cell C-terminal 6xHis-tagged
CTSB Recombinant Human Cathepsin B(CTSB),partial CSB-EP006185HU1 Human E.coli N-terminal GST-tagged
DPP4 Recombinant Human Dipeptidyl peptidase 4(DPP4) CSB-CF007139HU Human in vitro E.coli expression system N-terminal 10xHis-tagged
TMPRSS2 Recombinant Human Transmembrane protease serine 2(TMPRSS2),partial CSB-EP023924HU Human E.coli N-terminal 6xHis-tagged
TMPRSS2 Recombinant Human Transmembrane protease serine 2(TMPRSS2),partial CSB-YP023924HU Human Yeast N-terminal 6xHis-tagged
ACE2 Recombinant Human Angiotensin-converting enzyme 2(ACE2),partial CSB-MP866317HU Human Mammalian cell  
CD147 Recombinant Human Basigin(BSG),partial CSB-MP002831HU Human Mammalian cell
CD147 Recombinant Human Basigin(BSG),partial CSB-MP002831HUf3 Human Mammalian cell
NUP98 Recombinant Human Nuclear pore complex protein Nup98-Nup96(NUP98) ,partial CSB-MP016209HU Human Mammalian cell

2019 Novel Coronavirus

Based on the fact that the number of infected people in China has increased and outbreaks have occurred in many countries. On January 30, 2020, the World Health Organization announced that the 2019 Novel Coronavirus (SARS-CoV-2) was listed as Public Health Emergency of International Concern (PHEIC). At this point, the SARS-CoV-2 disease (COVID-19) disease is not only a battle in China, but also a global battle. So what exactly is the SARS-CoV-2? How does it spread? Where does SARS-CoV-2 come from? And how to treat it? Don’t worry, we will illustrate these questions one by one.

What is The Coronavirus?

Before introducing the SARS-CoV-2, let us understand what is a coronavirus. Coronaviruses are a large family of viruses that can cause respiratory illnesses such as the common cold. Almost everyone gets infected with coronaviruses at least once in their life, but symptoms are typically mild to moderate. Most coronaviruses are not dangerous, but some are. Those that cause Middle East respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS) can be deadly.
As the Figure 1 shows, coronaviruses are viruses that are spherical, have protrusions, and are crown-like. They are collectively referred to as coronaviruses. The virus has a diameter of 75 to 160 nanometers, and the virus genome is a continuous linear single-stranded RNA, and the molecular weight is usually (5.5 to 6.1) x106.

The coronavirus genome encodes a spike protein (S), an envelope protein, a membrane protein, and a nucleoprotein in this order. Among them, spike protein is the most important surface membrane protein of coronavirus.

What is The SARS-CoV-2?

The SARS-CoV-2 was discovered because of Wuhan Viral Pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family in 2003, together with SARS coronavirus (SARS CoV) in 2003 and MERS coronavirus (MERS CoV) in 2012. The alignment between SARS-CoV-2 and 2002 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. There is currently no specific treatment, but many symptoms can be managed, and need to be treated according to the clinical situation of the patient.
CUSABIO paid close attention to the progression of SARS-CoV-2. Once obtaining the virus gene sequence information, we quickly developed and produced SARS-CoV-2 related products. Targets include the Spike protein (S), N protein (N) and ACE2. Moreover, we also provide several products about coronavirus to meet the needs of scientific research.

How does SARS-CoV-2 Spread?
The virus is reportedly spreading from person-to-person in many parts of China and in some other countries by interacting with ACE2 from mucous membrane of eye, mouth and nose. On Jan. 30, the Centers for Disease Control and Prevention (CDC) identified the first case of person-to-person spread in the United States.
In terms of how one would catch the virus, the CDC says that human coronaviruses are most commonly spread between an infected person and others via:

  • The air (from viral particles from a cough or sneeze);
  • Close personal contact (touching or shaking hands);
  • An object or surface with viral particles on it (then touching your mouth, nose or eyes before washing your hands);
  • And rarely from fecal contamination.

What are The Symptoms of SARS-CoV-2 Infection?

As the Figure 2 shows, the typical symptoms of the SARS-CoV-2 infection include:

  • Main symptoms are fever, fatigue, and dry cough;
  • Nasal congestion, runny nose and other upper respiratory symptoms are rare;
  • Approximately half of the patients experienced dyspnea after one week, and the severe cases progressed rapidly to acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, and coagulopathy.

It is worth noting that in the course of severe and critically ill patients, there can be moderate to low fever, even without obvious fever. Some patients have mild onset symptoms and no fever. They usually recover after 1 week. Most patients have a good prognosis, and a few patients are critically ill and even die.

Where Does SARS-CoV-2 Come From?
Currently, the origin of SARS-CoV-2 also isn’t clear. But experts suppose that the origin still is wildlife like the other coronaviruses. Coronaviruses originate in animals-like camels, civets and bats-and are usually not transmissible to humans. But occasionally a coronavirus mutates and can pass from animals to humans and then from human to human, as such the case with the SARS epidemic in the early 2000s. China’s National Health Commission confirmed that 15 health care workers have become infected, indicating that the virus can spread from human to human.
Writing here, you may confuse that should I be concerned about pets (such as dog and cat) carring SARS-CoV-2? Exactly, there is no evidence suggested coronavirus in dogs and other pets. But, CDC recommends that people traveling to China avoid animals both live and dead.

How to Treat 2019 Novel Coronavirus?
In terms of SARS-CoV-2 treatment, there are no specific treatments for coronavirus infections and most people will recover on their own. So treatment involves rest and medication to relieve symptoms. A humidifier or hot shower can help to relieve a sore throat and cough. If you are mildly sick, you should drink a lot of fluids and rest.
Although there is no vaccine for the new coronavirus, researchers at the U.S. National Institutes of Health confirmed they were in preliminary stages of developing one. Officials plan to launch a phase 1 clinical trial of a potential vaccine within the next three months. Moreover, researchers are also working on gathering samples of the virus to design a therapy that will train patients’ immune cells to detect and destroy the virus.

How to Protect Yourself From Coronavirus?
Although there are no specific treatment for SARS-CoV-2 infection, we can take these measures to prevent us from it:

  • Wash your hands: wet your hands with clean, running water and apply soap.
  • Cover your mouth and nose with a tissue when you cough or sneeze, then throw the tissue and wash your hands. If you do not have a tissue to hand, cough or sneeze into your elbow rather than your hands.
  • Face masks offer some protection as they block liquid droplets.
  • Seek early medical help if you have a fever, cough and difficulty breathing, and share your travel history with healthcare providers.
  • If you have returned from an affected area in the last two weeks, stay indoors and avoid contact with other people for 14 days. This means not going to work, school or public areas.

SUPPORT

outstanding technical support

PRODUCT

we offer a full product guarantee

DELIVERY

we offer free delivery to UK universities and non profit organisations